Medical Ethnobiology and Ethnopharmacology in Latin AmericaView this Special Issue
Research Article | Open Access
Susan Skanderup Falkenberg, Inge Tarnow, Alfonso Guzman, Per Mølgaard, Henrik Toft Simonsen, "Mapuche Herbal Medicine Inhibits Blood Platelet Aggregation", Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 647620, 9 pages, 2012. https://doi.org/10.1155/2012/647620
Mapuche Herbal Medicine Inhibits Blood Platelet Aggregation
12 plant species traditionally used by the Mapuche people in Chile to treat wounds and inflammations have been evaluated for their direct blood platelet inhibition. Seven of the 12 tested plant species showed platelet inhibitory effect in sheep blood, and four of these were also able to inhibit the ADP- (5.0 M) and collagen- (2.0 g/mL) induced aggregations in human blood. These four species in respective extracts (in brackets) were Blechnum chilense (MeOH), Luma apiculata (H2O), Amomyrtus luma (DCM : MeOH 1 : 1) and Cestrum parqui (DCM : MeOH 1 : 1). The platelet aggregating inhibitory effects of A. luma (DCM : MeOH 1 : 1), and L. apiculata (H2O) were substantial and confirmed by inhibition of platelet surface activation markers.
Chile has an extraordinary variety of plants and animals, thanks to the latitudinal extent of the country and its great altitudinal range. The Chilean Winter Rainfall-Valdivian forest is one of the most exceptional and exposed biodiversity hotspots of the world. It encompasses approximately 40% of Chile’s land area and harbours both endemic flora and fauna. About 50% of the 4000 vascular plant taxa found in this area are endemic. Through collaboration, we have access to the traditional medicinal plants from this area [1–3]. The plants examined are traditionally used by the Mapuche people in Chile to treat wounds and associated infections, as shown in Table 1. This paper evaluates the platelet inhibitory capacity of 12 selected plant species.
Platelet receptors on the surface of the platelets determine the reactivity of platelets and have a wide range of agonists and adhesive proteins . Current antiplatelet therapies target key pathways of platelet activation, including surface receptors and signalling molecules. Aspirin has been the foundation of antiplatelet therapy for over 50 years, and it inhibits platelets by irreversibly acetylating Ser529 of cyclooxygenase 1 (COX1), thereby inhibiting thromboxane A2 formation by the platelets. Aspirin has been shown to reduce vascular death in high-risk patients by 15% and nonfatal vascular events by 30%, as evidenced by meta-analysis of over 100 randomized trials [8–10]. Several medicinal plants have direct or indirect antiplatelet effects, many through inhibition of COX1 or 2. Likewise, a variety of fruit extracts have been tested in vitro for their antiplatelet property, and tomatoes have been found to have a very high activity . It was showed that tomato extract inhibited both ADP- and collagen induced aggregation by up to 70% but not AA-induced platelet aggregation. Various fruit juices have also been tested, and some flavonoids have been established as inhibitors of collagen-induced platelet activity [12, 13]. The effect of flavonoids is well established, and for coffee, it was showed that the caffeine is not the inhibitor  but rather the phenolics that was also found inside the platelets. Many of the effects observed are often due to synergistic effects, which is also seen on tomato and grape juice, and the effect can be expected to be lower for the individual compounds [11–14].
The plants collected for this study have been chosen based on their use in the treatment of wounds and inflammatory diseases [1, 2]. Many inflammatory mechanisms are involved in wound healing. Especially, platelets plays a crucial role in haemostasis and thrombosis, and they also play an important role in wound healing, inflammation, antimicrobial host defence, angiogenesis, and tumour growth and metastasis . Therefore, plants used against these or related diseases have been collected. The plants examined in here are collected based on ethnopharmacological data from the Region de Los Lagos in southern Chile, part of the Chilean Winter Rainfall-Valdivian forest [3, 16, 17]. Deforestation threatens this area, and the evaluation of traditional medicine might help to preserve the area with its natural richness. Furthermore, the evaluation also contributes to the preservation of the Mapuche culture, and a sustainable production and/or collection of plants may create an economic foundation as an alternative to the felling of the rainforest.
The aim of the study was a screening of a variety of Mapuche herbal medicine for platelet inhibitory effects. Inhibition on platelet aggregation in sheep blood was chosen as an initial screening method due to the large volumes of blood needed. Plant extracts with activity in sheep blood were subsequently investigated for inhibitory effects on human blood platelets.
2. Material and Methods
2.1. Plant Material
The plant species in this study are traditionally used to treat wounds, wound infections, and/or inflammatory ailments by the Mapuche people. The collection have been conducted in February in the years 2001, 2003, 2005, 2006, and 2007 under the supervision of Alfonso Guzman . All plants have been collected in Region de Los Lagos located in Chile’s region X. Available plant parts were collected without destroying the population, for example, leaves, stems, flowers, and roots though mainly leaves are used for teas, the preferred preparation in Mapuche traditional medicine (Table 1) . After collection, the plant material was immediately dried at room temperature and transported to Denmark for further studies, where it was kept dry and in darkness until use. Voucher specimens are stored at the Botanical Garden and Museum, University of Copenhagen (C); see Table 1 for voucher specimen number.
2.2. Extraction and Sample Preparation
Dried material from 12 different species of Chilean plants was subjected to extraction. 5 mL DCM : MeOH 1 : 1 was added to 0.5 g dry plant material and exposed to ultrasonication for 30 minutes and filtration. This was repeated twice, and the combined extracts were evaporated to dryness. This procedure was repeated using MeOH and finally by H2O. The dried extracts were stored at −20°C until used for the aggregation assays. The screening was conducted in each of these three plant extracts, DCM : MeOH 1 : 1, MeOH, and H2O. Yield of extractions are given in Table 2.
*1: Aggregation curve and output % does not correlate, and the result is doubtful. |
*2: Aggregation curve is very flat, this is suspicious.
2.3. Preparation of Samples for Aggregation and Flow Cytometry Assays
The dried extracts were dissolved in DMSO : EtOH 1 : 4 in order to reach a concentration of 20 mg/mL, only extracts that was fully redissolved where taken forward. Tested extracts are listed in Table 2. The DMSO : EtOH samples were diluted in sterile filtered HEPES-tyrode’s buffer pH 7.4 (137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 12 mM NaHCO3, 0.4 mM Na2HPO4, 5.5 mM glucose, 10 mM HEPES) for aggregation assays, and in HEPES-tyrode’s buffer with 0.5% BSA for flow cytometry assays to a final concentration of 1 mg/mL. The DMSO : EtOH samples diluted in HEPES-tyrode’s buffer was added to PRP as a 1 : 10 dilution. HEPES-tyrode’s buffer containing 0.5% DMSO : EtOH 1 : 4 was used as vehicle control. Sample and vehicle control were incubated in PRP at 37°C for 30 min before aggregation experiments. Final concentration of plant extract and vehicle control in the aggregometer was 0.1 mg/mL. A pure MeOH aliquot was treated as an extract, and the effect of DMSO and MeOH was observed in all assays but did not show any significant effect.
2.4. Platelet Aggregation Assay
Platelet aggregation assays were performed in sheep and human blood in duplicates. Sheep blood was used for the bulk screenings, where a large volume of blood was needed. Human blood from the authors SSF (female, 32) and IT (female, 37) was used for selected extracts to verify an inhibitory effect seen in sheep blood at first screening. None of the human volunteers had been exposed to antiplatelet medication for at least 2 weeks prior to blood sampling. Venous blood was drawn with minimal stasis using a 21 G needle into Vacutainer tubes containing 3.2% (0.129 M) sodium citrate (1 : 9), after discarding the first 2 mL.
Platelet-rich plasma (PRP) was prepared by centrifugation of citrated blood at 150 ×g for 10 minutes (human blood) or 1200 ×g for 3 minutes (sheep blood) at 21°C. Autologous platelet-poor plasma (PPP) was prepared by centrifugation of the remaining blood at 3000 ×g for 10 min at 21°C. In each sample, the platelet count of the PRP was determined by an automated counter (Medonic CA 620Vet, Boule Medical AB, London, UK), and based on the count PRP was adjusted to the standard concentration (250,000 platelets/μL). Platelet aggregation was performed by standard procedures (Chronolog VS700, Chronolog Corp., Haverton, Pa, USA) with the following modifications: 225 μL PRP and 25 μL agonist were used in all experiments. Platelet poor plasma with DMSO : EtOH samples diluted 1 : 20 in HEPES-tyrode’s buffer was used as reference to eliminate bias of the extract colouring in the test. Final concentrations of the agonists in sheep samples were 5 μg/mL collagen (Chronolog Corp, Haverton, Pa, USA) and 5 μM adenosine diphosphate (ADP—Bio/Data, Horsham, PA) and 2 μg/mL collagen and 5 μM ADP in human samples. Extract and vehicle control samples were analysed in parallel.
Aggregation response was recorded using the Aggrolink software (Chronolog Corp). Maximal aggregation (MA) was recorded in order to obtain a % inhibition of plant extract, comparing the vehicle control (HEPES-tyrode’s buffer including BSA) with that of the plant extract %inhibition = (MA vehicle control − MA extract)/MA vehicle control * 100%.
The experiments were approved by the Animal Experiments Inspectorate under the Danish Ministry of Justice. All human blood used was drawn from the authors themselves.
2.5. Initial Experiments in Aggregometer
Arachidonic acid (AA), ADP and collagen were tested in several concentrations in sheep blood in order to find the most suitable agonists and the appropriate concentrations of these.
Based on the results from the initial experiment it was decided to test AA in 500 μM, ADP in 5.0 μM, and collagen in 2.5 μg/mL in an initial experiment, and from that, it was decided to use ADP and collagen to all future experiments in the aggregometer. The tested ADP concentration at 5.0 μM was suitable, whereas the collagen concentration was increased from 2.5 μg/mL to 5.0 μg/mL. The aggregation percentage in the collagen-induced reaction with vehicle control was 61%, and by increasing the concentration of agonist, the aggregation percentage would hopefully also increase in order to get closer to the desired 70%. AA was not used in any further experiments.
ADP and collagen were used as agonists based on the initial experiments. For human blood, it was decided to lower the collagen concentration to 2.0 μg/mL due to the observed aggregation. The ADP concentration was the same (5.0 μM) as in the experiment with sheep blood.
To establish the plant extract testing concentration, the MeOH extract of the pharmacologically well described of Drimys winteri  was tested in three different concentrations, 10, 1, and 0.1 mg/mL. All three gave high inhibition with 0.1 mg/mL yielding 38% (ADP agonist) and 90% (collagen agonist) inhibition of sheep blood aggregation. Taking into account that the 0.1 mg/mL was also significantly easier to dissolve in the testing buffers, it was decided to use this concentration throughout the screening. This would still give positive results for potent aggregation inhibitors.
2.6. Flow Cytometry
The DMSO : EtOH samples from Amomyrtis luma and Luma apiculata (1 mg/mL) diluted in HEPES-tyrode’s buffer containing BSA pH 7.4 was used for flow cytometry experiments. 0.5% EtOH in HEPES-tyrode’s buffer with BSA was used as vehicle control. Citrated human blood was incubated with DMSO : EtOH/HEPES-tyrode’s samples (final concentration of 0.1 mg/mL) or vehicle control at 37°C in 30 minutes.
Samples were assayed within 15 minutes from venipuncture. Microcentrifuge tubes were prepared containing a mixture of either HEPES-Tyrode’s buffer, phycoerythrin (PE) conjugated anti-CD62P (Santa Cruz Biotechnology, Santa Cruz, Calif, USA), fluorescein isothiocyanate (FITC) conjugated PAC-1 (Becton Dickinson, San Jose, Calif, USA), or HEPES-Tyrode’s buffer, PE-Cy5-conjugated anti-CD42b (Becton Dickinson), fluorescein isothiocyanate (FITC) conjugated PAC-1 (Becton Dickinson, San Jose, Calif, USA) and eptifibatide. To both mixes platelet agonist was added for the detection of platelet surface P-selectin and activated GPIIb/IIIa. Pilot experiments using several different agonist concentrations were performed to identify agonist concentrations giving maximal and submaximal platelet activation. Final concentrations of agonists in the reaction mixture were 1 or 5 μM of thrombin receptor activating peptide (TRAP, Sigma-Aldrich, Brondby, Denmark), 0.5 or 20 μM of ADP (Bio/Data Co., Horsham, Pa, USA), or no agonist (HEPES-Tyrode’s buffer). All ADP and TRAP dilutions were made as batches and stored at −20°C along with vehicle control for the controls to minimize dilution variation. Antibody mixtures were prepared as batches and kept at 4°C. After incubation, P-selectin and activated GPIIbIIIa samples were fixed by 1% formaldehyde in HEPES-saline. Samples were analyzed in an FACSCalibur (Becton Dickinson) flow cytometer. Platelets were identified by light scatter properties and expression of CD42b. All samples were tested in triplicates.
3.1. Platelet Aggregation in Sheep Blood
After conducting the initial experiments, a total of 33 extracts, from 12 different plants were screened in ADP (5.0 μM) and collagen (5.0 μg/mL) induced aggregations in the aggregometer. Table 2 shows the average reading of duplicates and whether or not the plant extracts were able to inhibit ADP and collagen induced aggregation. All extract was compared towards the vehicle control and if the observed aggregation was 20% lower for extract test than for the vehicle is was concluded that the extract inhibited aggregation. Additionally, all extracts was tested with two different inducers, this further support the validity of the inhibition results.
Plant samples that in a convincing way were able to inhibit the aggregation in sheep blood were subsequently tested in a similar experiment with human blood. The below seven plants in the respective extracts were the ones chosen to be tested again.
The DCM : MeOH 1 : 1 extracts of Amomyrtus luma, Blechnum chilense, Cestrum parqui, Lomatia ferruginea, and Pseudopanax laetevirens were active as were the MeOH extracts of A. luma, Anthoxanthum utriculatum B. chilense, C. parqui, Luma apiculata, and P. laetevirens, and the water extracts of A. luma, C. parqui, and L. apiculata. These samples were all chosen to be tested in human blood.
3.2. Platelet Aggregation in Human Blood
Seven of the species tested in sheep blood was tested in human blood. The activity is listed in Table 3. The four plants A. luma (DCM : MeOH 1 : 1 extract), B. chilense (MeOH extract), C. parqui (DCM : MeOH 1 : 1 extract), and L. apiculata (H2O extract) showed inhibitory effect in both sheep and human blood in both ADP- and collagen induced aggregations (see Tables 2 and 3). Furthermore, the H2O extract from A. luma showed inhibition in the collagen induced aggregation.
3.3. Flow Cytometry
In order to confirm the obtained results from the aggregation experiments the A. luma DCM : MeOH 1 : 1 extract and the L. apiculata H2O extract were tested for inhibition of platelet surface activation markers flow cytometry.
Table 4 shows the tested extracts and the percent inhibition of PAC1 MFI and CD62P (P-selectin) MFI by addition of ADP (0.5 μM and 20 μM) and the human specific inducer TRAP (1.0 μM and 5.0 μM). PAC1 and CD62P are both markers of platelet activation, and in order to be assigned an inhibitory effect the extracts should inhibit both activation markers using both agonists at all concentrations.
The extracts from L. apiculata and A. luma showed clearly inhibitory effect of both PAC1 MFI and CD62P MFI in the tested ADP concentrations as well as with the addition of 1.0 μM TRAP, whereas only a slight inhibitory effect is observed when 5.0 μM TRAP was added. TRAP was used in the flow cytometry assays since it is a human specific platelet inducer.
The four plants Amomyrtus luma, Blechnum chilense, Cestrum parqui, and Luma apiculata showed inhibitory effect in both sheep and human blood in both ADP and collagen induced aggregations. Of these L. apiculata (H2O extract) and A. luma (DCM : MeOH 1 : 1 extract) was the most prominent candidates for further examinations. The two extracts were examined using platelet specific markers PAC1 and CD62P and the human-specific inducer TRAP and ADP in a flow cytometry assay. PAC1 and CD62P (P-selectin) does not bind to resting platelets but only to activated platelets . These studies showed clear platelet inhibitory effect on platelet surface activation markers by the two markers as shown in Table 4. The effect observed in the flow cytometry confirms the results seen in the aggregometer.
The ethanol extract of the leaves of A. luma has been shown to contain 1-phenylpentan-3-one (4.6/8.5%) and 1-phenylhexan-3-one (3.5/12.3%) as well as β-caryophyllene oxide (10.7/6.6%) and linalool (59.3/11.3%) , of these the β-caryophyllene oxide has been shown to spontaneously aggregate blood platelets  at 100 μg/mL concentrations. This effect contradicts the observed effect of the extract, where aggregations was inhibited and suggest a strong inhibition of the organic extracts of A. luma since β-caryophyllene oxide would have been extracted with both DCM : MeOH 1 : 1 and to some extend also MeOH. The presence of β-caryophyllene oxide could be part of the explanation on why no inhibition was observed for the MeOH extract using ADP as an inducer. Further studies are needed to determine the active constituents in A. luma.
The MeoH extracts of B. chilensis have previously been shown to have antimicrobial effects . L. apiculata have previously been shown to have xanthine oxidase inhibitory activity (30% inhibition at 50 μg/mL EtOH : H2O 7 : 3 extract) , and antiviral activity on herpes (IC50 = 100 μg/mL, EtOH extract) . But none of these studies provides information to what could be active constituent, and no phytochemical data was found for these two species. COX inhibitory activity indirectly inhibiting P-selectin expression on human platelets . It has been demonstrated that caffedymine from cocoa, have COX inhibitory activity, with 43% inhibition of COX-1 at 0.01 μM, and that caffedymine suppress P-selectin (CD62P) expression on platelets by 33% at a concentration of 0.05 μM . The inhibition of COX enzymes may be a main contributing factor to suppressing P-selectin expression , which could be the effect observed with extracts of L. apiculata and A. luma. In order to confirm or invalidate this theory, COX inhibitory effect of L. apiculata and A. luma would have to be examined. Several plant extracts have already been tested for their COX activity  and this would need to evaluated along with determination of the active constituents.
It has previously been shown, that a MeOH : H2O 1 : 1 extract from C. parqui was able to inhibit aggregation of human blood platelets induced by ADP . This confirms that some extracts from C. parqui are able to inhibit ADP induced platelet aggregations. However, the same was not observed in an AA-induced platelet aggregation, which implies that, the extracts anti-inflammatory activity did not implicate the inhibition of the cyclooxygenase pathway, that has been seen in other studies . A suggestion is that the extract inhibited a site upstream of AA metabolism, since the case might be that ADP has triggered the release of AA in the pathway . These data could explain the data observed and the two datasets suggest that C. parqui contains several active constituents. The plant itself have long been known to cause poisoning in cows, and it has been shown that the toxicity is in the organic phase that contained low molecular weight phenols , among these flavonoids that as mentioned have been shown to have antiplatelet activity. With more than 150 publication on C. parqui and its pharmacology and several toxic and pharmacologically active terpenoids isolated from the plant  further studies are not of high priority.
In the present work, four Chilean plant species were shown to inhibit platelet aggregating induced by ADP and collagen in both sheep and human blood. The four species were Blechnum chilense (MeOH extract), Luma apiculata (H2O extract), Amomyrtus luma (DCM : MeOH 1 : 1 extract) and Cestrum parqui (DCM : MeOH 1 : 1 extract). The platelet aggregating inhibitory effects of A. luma (DCM : MeOH 1 : 1 extract) and L. apiculata (H2O extract) were furthermore confirmed by inhibition of platelet surface activation markers.
At present, there is still a great need for preventative and therapeutic, anticoagulant medicine, and plants and their fruits seem to constitute possible alternatives to drugs currently used. It is of great interest to explore this inhibition further for the three species B. chilense, L. apiculata, A. luma.
The authors wish to thank Jaime Zapata, Universidad de Los Lagos, Osorno, Chile for identification of the plant material. They are grateful to Beckett-Fonden (HTS) for financial support of the project.
- H. T. Simonsen, A. Adsersen, L. Berthelsen, S. B. Christensen, A. Guzmán, and P. Mølgaard, “Ethnopharmacological evaluation of radal (leaves of Lomatia hirsuta) and isolation of 2-methoxyjuglone,” BMC Complementary and Alternative Medicine, vol. 6, article 29, 2006.
- H. T. Simonsen, C. Riedel, L. B. Gade, C. P. Jebjerg, A. Guzman, and P. Mølgaard, “Chemical composition and antibacterial activity of the leaf essential oil of Baccharis magellanica (Lam.) pers. and Baccharis elaeoides remy from Chile,” Journal of Essential Oil Research, vol. 21, no. 4, pp. 377–380, 2009.
- P. Mølgaard, J. G. Holler, B. Asar et al., “Antimicrobial evaluation of Huilliche plant medicine used to treat wounds,” Journal of Ethnopharmacology. In press.
- H. M. Niemeyer, “Biologically active compounds from chilean medicinal plants,” in Phytochemistry of Medicinal Plants, J. T. Arnason, R. Mata, and J. T. Romeo, Eds., pp. 137–160, Plenum Press, New York, NY, USA, 1995.
- A. M. Bacigalupo, “Rituales de género para el orden cósmico: luchas chamánicas Mapuche por la totalidad,” Scripta Ethnologica, vol. 26, pp. 9–38, 2004.
- M. C. Torri, “Medicinal plants used in Mapuche traditional medicine in Araucanía, Chile: linking sociocultural and religious values with local heath practices,” Complementary Health Practice Review, vol. 15, no. 3, pp. 132–148, 2010.
- K. J. Clemetson, “Platelet receptors,” in Platelets, A. D. Michelson, Ed., pp. 65–85, Academic Press, San Diego, Calif, USA, 2002.
- C. Baigent, C. Sudlow, R. Collins, and R. Peto, “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002.
- S. Guthikonda, E. I. Lev, R. Patel et al., “Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin,” Journal of Thrombosis and Haemostasis, vol. 5, no. 3, pp. 490–496, 2007.
- M. M. C. Hovens, J. D. Snoep, J. C. J. Eikenboom, J. G. van der Bom, B. J. A. Mertens, and M. V. Huisman, “Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review,” American Heart Journal, vol. 153, no. 2, pp. 175–181, 2007.
- A. K. Dutta-Roy, L. Crosbie, and M. J. Gordon, “Effects of tomato extract on human platelet aggregation in vitro,” Platelets, vol. 12, no. 4, pp. 218–227, 2001.
- J. G. Keevil, H. E. Osman, J. D. Reed, and J. D. Folts, “Grape juice, but not orange juice or grapefruit juice, inhibits human platelet aggregation,” Journal of Nutrition, vol. 130, no. 1, pp. 53–56, 2000.
- B. Wright, L. A. Moraes, C. F. Kemp et al., “A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids,” British Journal of Pharmacology, vol. 159, no. 6, pp. 1312–1325, 2010.
- F. Natella, M. Nardini, F. Belelli et al., “Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation,” British Journal of Nutrition, vol. 100, no. 6, pp. 1276–1282, 2008.
- A. D. Michelson, M. R. Barnard, L. A. Krueger, A. L. Frelinger, and M. I. Furman, “Evaluation of platelet function by flow cytometry,” Methods, vol. 21, no. 3, pp. 259–270, 2000.
- D. Estomba, A. Ladio, and M. Lozada, “Medicinal wild plant knowledge and gathering patterns in a Mapuche community from North-Western Patagonia,” Journal of Ethnopharmacology, vol. 103, no. 1, pp. 109–119, 2006.
- P. J. Houghton and J. Manby, “Medicinal plants of the Mapuche,” Journal of Ethnopharmacology, vol. 13, no. 1, pp. 89–103, 1985.
- A. Guzmán and S. Nilian, Medicinal Plants Used by Huilliche Indians, Viking Books, Southern Chile, 2000.
- A. D. Michelson, “Flow cytometry: a clinical test of platelet function,” Blood, vol. 87, no. 12, pp. 4925–4936, 1996.
- P. Weyerstahl, H. Marschall, and L. R. Landrum, “Constituents of the leaf extract of Amomyrtus meli (R.A.Philippi) Legrand et Kausel, Amomyrtus luma (Molina) Legrand et Kausel and of Amomyrtella guili (Speg.) Kausel,” Flavour and Fragrance Journal, vol. 7, no. 5, pp. 247–251, 1992.
- W. Y. Lin, Y. H. Kuo, Y. L. Chang et al., “Anti-platelet aggregation and chemical constituents from the rhizome of Gynura japonica,” Planta Medica, vol. 69, no. 8, pp. 757–764, 2003.
- C. Theoduloz, P. Pacheco, and G. Schmeda-Hirschmann, “Xanthine oxidase inhibitory activity of Chilean Myrtaceae,” Journal of Ethnopharmacology, vol. 33, no. 3, pp. 253–255, 1991.
- P. Pacheco, J. Sierra, G. Schmeda-Hirschmann, C. W. Potter, B. M. Jones, and M. Moshref, “Antiviral activity of Chilean medicinal plant extracts,” Phytotherapy Research, vol. 7, no. 6, pp. 415–418, 1993.
- J. B. Park, “Caffedymine from cocoa has COX inhibitory activity suppressing the expression of a platelet activation marker, P-selectin,” Journal of Agricultural and Food Chemistry, vol. 55, no. 6, pp. 2171–2175, 2007.
- R. S. Talhouk, C. Karam, S. Fostok, W. El-Jouni, and E. K. Barbour, “Anti-inflammatory bioactivities in plant extracts,” Journal of Medicinal Food, vol. 10, no. 1, pp. 1–10, 2007.
- D. Shehnaz, F. Hamid, F. T. Baqai, and V. U. Ahmad, “Effect of the crude extract of Cestrum parqui on carrageenin-induced rat paw oedema and aggregation of human blood platelets,” Phytotherapy Research, vol. 13, no. 5, pp. 445–447, 1999.
- N. Backhouse, C. Delporte, R. Negrete et al., “Antiinflammatory and antipyretic activities of Cuscuta chilensis, Cestrum parqui and Psoralea glandulosa,” Pharmaceutical Biology, vol. 34, no. 1, pp. 53–57, 1996.
- B. D'Abrosca, M. DellaGreca, A. Fiorentino, P. Monaco, and A. Zarrelli, “Low molecular weight phenols from the bioactive aqueous fraction of Cestrum parqui,” Journal of Agricultural and Food Chemistry, vol. 52, no. 13, pp. 4101–4108, 2004.
- B. D'Abrosca, M. DellaGreca, A. Fiorentino et al., “Structural characterization of phytotoxic terpenoids from Cestrum parqui,” Phytochemistry, vol. 66, no. 22, pp. 2681–2688, 2005.
Copyright © 2012 Susan Skanderup Falkenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.